Printed From BioPortfolio.com
Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma
00:00 EST 1 Jan 2018 | 2 Minute Medicine
1. Patients with refractory diffuse large B-cell or follicular lymphoma demonstrated high rates of remission when treated with anti-CD19 directed chimeric antigen receptor (CAR) T-cell therapy. 2. Serious adverse events noticed in this cohort included cytokine release syndrome and encephalopathy. Evidence Rating Level: 3 (Average) Study Rundown: Diffuse large B-cell lymphoma and follicular lymphoma comprise […]
Original Article: Chimeric antigen receptor T-cell therapy elicits treatment response in patients with refractory B-cell lymphoma
